1 / 10

Contract Support for Frederick National Cancer Research

A re-competition for contract support of Frederick National Laboratory for Cancer Research, a valuable asset advancing cancer research, with critical evaluation factors and clear schedule outlined by NCI.

bcanty
Download Presentation

Contract Support for Frederick National Cancer Research

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Contract Re-Competition Announced Contract Support for the Frederick National Laboratory for Cancer Research: A Federally Funded Research and Development Center sponsored by the NIH/NCI

  2. General Information: Incumbent Contract • The incumbent contract for the Frederick National Laboratory for Cancer Research (FLNCR), a Federally Funded Research and Development Center (FFRDC) contract was awarded on 09/26/2008 • The incumbent contract was awarded for a ten year period of performance • The incumbent total contract value is ~$6,000,000,000 • The incumbent contract was awarded to SAIC-Frederick, Inc.; (now Leidos Biomedical Research, Inc. via name change)

  3. Re-competition • The current contract supporting the Frederick National Laboratory for Cancer Research (FNLCR) is coming to a close. Due to the size and scope of the FNLCR, it is expected that a re-competition of this contract will take up to 2 years.   The FNLCR will benefit from a contract that establishes a long-term relationship between NCI and an entity that will allow the Frederick National Lab to attract high-quality personnel and provide flexible and rapid response capability to the changing needs of the cancer research community.  The NCI believes the FNLCR provides the potential for dynamic collaborations with all entities, including academia, and we are, therefore, encouraging those collaborations in this re-competition. • NCI contemplates the new contract will be awarded for a term of 10 years, however, this is subject to change. • NCI is still in the planning phases of this acquisition, but anticipates an Indefinite Delivery – Indefinite Quantity (IDIQ) contract with both severable and non-severable tasks. Options may be included. • The NCI contemplates the source selection process utilized will reflect a best value process with an award to other than the lowest priced offeror. • All evaluation factors and significant sub-factors and their relative importance will be clearly stated in the solicitation. • Technical capability will be of paramount importance in this acquisition • Subcontracting plan will be a critical evaluation factor

  4. Re-competition • The NCI contemplates the following general schedule • Draft RFP Issuance 4th Quarter FY15 • Pre-proposal Conference 1st Quarter FY16 • RFP Issuance 1st Quarter FY16 • Receipt of Proposals 2nd Quarter FY16 • Contract Award is planned in January 2017, however, this is subject to change.

  5. Re-competition • The FNLCR is a unique asset and plays an important role in advancing cancer research. To make the most of this resource, NCI is looking to award the contract supporting the Frederick National Lab to an entity with experience and expertise in advancing biomedical research, including proactive and innovative approaches to a complex research agenda, and an established record of providing flexible and rapid response capabilities. Consequently, we anticipate seeking proposals from organizations with a proven history of pursuing scientific research, an ability to find and engage collaborators in a productive research environment, and experience managing a national resource, such as an FFRDC. • NCI believes that academic partnerships, involvement, or a highly-specialized organization that has been developed in the pursuit of furthering biomedical research (similar in nature to the traditional practices of an educational institution) is needed to forward the research agenda of this magnitude. • NCI does not have a predefined model in mind. We look forward to receiving responses from any qualified entity that is capable of operating, managing, and administering a contract of this type and size, including universities; a consortium of universities; other nonprofit organizations; industrial firms identified as autonomous organizations (i.e., identified separately from any parent organization); collaborative partnerships, such as an LLC; or some other legal arrangement formed for the purpose of operating an FFRDC.

  6. Re-competition: Funding • The incumbent contract is valued at $6B, in total. • The NCI anticipates the new award will be an Indefinite Delivery-Indefinite Quantity (IDIQ) type contract. That means, work will be conducted via individually awarded task orders. • The NCI anticipates most, but not all, work will be cost reimbursement in nature and a fixed fee will be negotiated for fee earning entities • The new contract ‘s funding level will consist of a contract CEILING. A ceiling is a maximum contract value that cannot be exceeded by the total of all combined tasks awarded under the contract. This is not a direct funding level. It is a maximum. Each task will be negotiated and will include a total funding value. • The NCI anticipates the ceiling for the new award will not exceed $8.58B • Since work will be funded by task order, it is fully expected that this ceiling may not be achieved. • Due to the size and complexity of this contract, there are several risk factors that NCI anticipates monitoring throughout performance, including, but not limited to: research progression, complexity and achievement of mission, technology integration and advancement, emergency response capability, personnel achievement/performance/fit/turnover/learning curve.

  7. Re-competition: Programs • The general areas below represent research and research support programs under the FNLCR: • Basic and Translational – areas of research may include cancer, AIDS and other diseases. Activities may include research, technical support, laboratory management, administrative support, and project management. Example: Rat Sarcoma (RAS) • Clinical– areas of research may include cancer, AIDS and other diseases domestically and internationally. Activities may include conducting clinical trials; monitoring, testing, and oversight of clinical research; and process transfer/development and pilot production of cGMP experimental therapeutics and vaccines. Example: Biopharmaceutical Development Program (BDP) • Animal– provide expertise for laboratory animal medicine, including acquisition and holding, technical and health diagnostic support to investigators. Activities may include animal modeling experimentation, generation of genetically engineered animals, cryopreservation, histology, pathology and small animal imaging. Example: Small Animal Imaging Program

  8. Re-competition: Programs • Advanced Technologies – evaluate, recommend, develop, implement and apply advanced technologies in support of government research initiatives, projects and programs as required. Areas of activities may include nanotechnology, genomics, high performance computing, research informatics, proteomics and metabolomics • Information Systems and Information Technologies – research, evaluate, recommend, develop, implement and apply information systems and computer services in support of government research initiatives. Activities may include bioinformatics and biostatistics support, information systems and technology management, and computer services. • Repository– provide technical expertise in the operation and cost control of repositories at various locations.  This is to include oversight of repository operations and provision of facilities as needed.

  9. Pre-Proposal Conference Planned • Additional information concerning the competitive process for the re-competition will be announced on the government-wide point of entry, Federal Business Opportunities (FedBizOpps) at www.fbo.gov, as well as at the FNLCR Acquisition Portal at http://ncioa.cancer.gov/oa-internet/fnlcr/index.html. Information posted on FedBizOpps takes precedence over information provided elsewhere. • Additionally, the NCI Office of Acquisitions will host a pre-proposal conference designed to showcase the FNLCR and the innovative work currently being conducted there. This will be a two-day event, scheduled for October 1-2, 2015. The event will begin on Thursday, October 1, 2015, at the National Institutes of Health, Natcher Conference Center, in Bethesda, MD, and will consist primarily of presentations and information concerning the FNLCR’s mission and purpose, an overview of its scientific programs, and an overview of its management, facilities, and business operations. In addition, an overview of the draft Request for Proposals (RFP) and submission instructions is planned. On Friday, October 2, 2015, NCI will conduct guided tours of the FNLCR facilities in Frederick, MD. • To register to attend this pre-proposal conference or to obtain further details, information will be posted on the FNLCR Acquisition Portal under "Events" at http://ncioa.cancer.gov/oa-internet/fnlcr/index.html as updates become available.

  10. Additional Information • For more background information on the FNLCR please visit the following sites: • Frederick National Laboratory for Cancer Research (FNLCR) http://frederick.cancer.gov • National Cancer Advisory Board (NCAB) http://deainfo.nci.nih.gov/advisory/ncab/ncab.htm • Frederick National Laboratory Advisory Committee (FNLAC) http://deainfo.nci.nih.gov/advisory/fac/fac.htm • If you have questions, please email the FNLCR Acquisition Team at: FNLCR_ACQinfo@nih.gov (FNLCR_ACQinfo@nih.gov).

More Related